AIM ImmunoTech CEO Equels buys 38,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
AIM ImmunoTech Inc. CEO & President Thomas K. Equels purchased 38,000 shares of common stock at $0.135 per share on November 16, 2026. He directly held 366,095 shares after the purchase. No Rule 10b5-1 plan is reported.
Insider Trade Summary
Net Buyer: 38,000 shares
Net Buy
1 txn
Insider
Equels Thomas K
Role
CEO & President
Bought
38,000 shs ($5K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 38,000 | $0.135 | $5K |
Holdings After Transaction:
Common Stock — 366,095 shares (Direct)
Key Figures
Shares purchased: 38,000 shares
Purchase price: $0.135 per share
Direct holdings after purchase: 366,095 shares
3 metrics
Shares purchased
38,000 shares
Thomas K. Equels purchase on November 16, 2026
Purchase price
$0.135 per share
Thomas K. Equels purchase on November 16, 2026
Direct holdings after purchase
366,095 shares
Thomas K. Equels position after the November 16, 2026 purchase
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.